Search Results 341-350 of 7479 for albumin

  1. A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers - Mayo Clinic

    - Albumin >= 3.0 g/dL - Prothrombin time (PT)/activated partial thromboplastin time (aPTT) =< 1.5 x ULN (This applies only to patients who do not receive ...

  2. EHR-Based Genomic Discovery - Atherosclerosis and Lipid Genomics Laboratory - Mayo Clinic Research

    The research team in Dr. Kullo's Atherosclerosis and Lipid Genomics Laboratory is conducting electronic health record (EHR)-based genetic studies.

  3. A Study to Develop a Resource (bank) of Biospecimens and Data Collected from Individuals with Liver Disease and Without Liver Disease - Mayo Clinic

    About this study. The purpose of this study is to facilitate discovery and development of novel biomarkers of risk and early detection, etiologic factors ...

  4. ... ALBUMIN SERUM/PLASMA/WHOLE BLD,60,64.00, 301000023,HC ALBUMIN URINE/OTHER SOURCE QUANT,69,73.00, 301000024,HC ALCOHOLS QUANT ASSAY,132,140.00, 301000025 ...

  5. Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma - Mayo Clinic

    Serum albumin < 2.5 g/dL; Serum creatinine > 1.5× ULN (or a calculated creatinine clearance < 60 mL/min/1.73 m2). Patients with a significant cardiovascular ...

  6. First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b - Mayo Clinic

    Albumin ≥ 3.0 g/dL. During the study, female study participants of child-bearing potential must use a highly effective non-hormonal form of contraception ...

  7. Aplastic anemia - Symptoms & causes - Mayo Clinic

    Your body stops producing enough new blood cells in this rare and serious condition, possibly causing fatigue, higher risk of infections and uncontrolled ...

  8. Study of Sacituzumab Govitecan (IMMU-132) in Metastatic or Locally Advanced Unresectable Urothelial Cancer - Mayo Clinic

    ... albumin > 3 g/dL). Docetaxel will only be option in TPC arm for subjects with a total bilirubin ≤ 1 x IULN, and an AST and/or ALT ≤ 1.5 x IULN if alkaline ...

  9. A Study to Assess Financial Burden and Its Impact on Quality of Life in Patients with Plasma Cell Disorders - Mayo Clinic

    The purpose of this study is to evaluate the magnitude of financial toxicity in newly diagnosed and relapsed multiple myeloma (MM) and amyloidosis (AL) patients ...

  10. Gastroenterology and Hepatology - Department home - Mayo Clinic

    These mainly include conditions involving the pancreas, liver, gallbladder, esophagus, stomach, small intestine and colon. With 13 specialty groups and more ...